Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | ACHE | P22303 | 5/20 | 0.61 |
| ▸ | BCHE | P06276 | 4/20 | 0.61 |
| ▸ | BACE1 | P56817 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5188069 | 0.99 | SIGMAR1 (0.67) | SIGMAR1MAPK1ACHEBCHEBACE1 | |
| SCHEMBL3602487 | 0.89 | SIGMAR1 (0.73) | SIGMAR1MAPK1ACHEBCHEBACE1 | |
| Hydrochloric Acid SCHEMBL11098239 | 0.88 | SIGMAR1 (0.72) | SIGMAR1MAPK1ACHEBCHEBACE1 | |
| SCHEMBL2263432 | 0.86 | KMT2A (0.55) | SIGMAR1MAPK1ACHEBCHEBACE1 | |
| SCHEMBL3658594 | 0.85 | BCHE (0.54) | SIGMAR1MAPK1ACHEBCHEBACE1 | |
| SCHEMBL1813802 | 0.82 | ALDH1A1 (0.55) | SIGMAR1MAPK1ACHERAB9AMEN1 | |
| SCHEMBL1813803 | 0.82 | ALDH1A1 (0.55) | SIGMAR1MAPK1ACHERAB9AMEN1 | |
| SCHEMBL2315613 | 0.81 | SIGMAR1 (1.00) | SIGMAR1MAPK1 | |
| SCHEMBL7467264 | 0.80 | ACHE (0.71) | SIGMAR1ACHEBCHEBACE1MEN1 | |
| SCHEMBL30178567 | 0.80 | ACHE (0.59) | SIGMAR1ACHEBCHEBACE1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773789-A1 | PROCESS FOR THE PREPARATION OF 3-(4-PIPERIDINYL)- 2,3,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-2(1H)-ON | Boehringer Ingelheim International GmbH (DE) | 2007-04-18 | — | — | EP | claimed |
| US-7141667-B2 | 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-28 | — | — | US | claimed |
| WO-2006010511-A1 | METHOD FOR PRODUCING 3-(4-PIPERIDINYL)-2,3,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-2(1H)-ON | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20060019946-A1 | 3-(4-Piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | US | claimed |
| EP-1619187-A1 | Process for the preparation of 3-(4-piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2006-01-25 | — | — | EP | claimed |
| EP-3708566-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2023-02-08 | — | — | EP | disclosed |
| CN-107428744-B | Novel heterocyclic compounds and their use in medicine and cosmetics | 盖尔德马研究及发展公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-3708566-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2020-09-16 | — | — | EP | disclosed |
| EP-3237403-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2020-05-06 | — | — | EP | disclosed |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
| EP-3237403-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2007131020-A2 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007131020-A2 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259851-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-20070259851-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-20070259851-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-7141667-B2 | 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-28 | — | — | US | disclosed |
| US-20060019946-A1 | 3-(4-Piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | US | disclosed |
| EP-1619187-A1 | Process for the preparation of 3-(4-piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019946-A1 | 3-(4-Piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one | HTR1A, HTR1D, HTR1B | SIGMAR1 616/4885MAPK1 2673/4885ACHE 1182/4885 |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | SIGMAR1 327/4885MAPK1 2395/4885ACHE 367/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | SIGMAR1 352/4885MAPK1 2393/4885ACHE 287/4885 |
| US-20070259851-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | CALCR, BDKRB2, CALCRL | SIGMAR1 907/4885MAPK1 1541/4885ACHE 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.